• By ICR Secretariat
  • Posted Tuesday, July 9, 2019

NICE OK for life-extending Vizimpro in lung cancer

http://www.pharmatimes.com/news/nice_ok_for_life-extending_vizimpro_in_lung_cancer_1293312

Pfizer’s Vizimpro (dacomitinib) has been recommended as a first-line treatment option for people with locally advanced or metastatic non-small-cell lung cancer (NSCLC).